A $3.15bn deal follows a December 2024 option agreement.
ApexOnco Front Page
Recent articles
The groups spend big on Terns and Arcellx.
But Tevimbra’s role looks shaky as adverse events loom.
Four months after yielding first-in-human data INCA33890 enters phase 3.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
Mocertatug rezetecan is starting its first western pivotal trials.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
